ATLANTA--(BUSINESS WIRE)--March 31, 2006--Serologicals Corporation (NASDAQ: SERO) announced today that it has completed its previously announced acquisition of Cytomyx Ltd., a wholly owned subsidiary of Cytomyx Holdings Plc (AIM: CYX). Based in Cambridge, U.K., Cytomyx Ltd. is a leading provider of ion channel cell lines and drug discovery services. With 23 distinct ion channel cell lines commercially available, and more in its pipeline, Cytomyx Ltd. offers the largest portfolio of distinct ion channel cell lines in the marketplace today. Serologicals paid U.S. $7 million for the stock of Cytomyx Ltd.
